Adult Dosing
Stimulation of follicular development
- 75 IU SC q24 hrs until adequate follicular development
- Max: 14 days
Notes:- Administer concomitantly with 75-150 IU of follitropin alfa
- To complete follicular development and effect ovulation in the absence of an endogenous LH surge, administer human chorionic gonadotropin (hCG) one day after the last dose of lutropin alfa
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Lutropin alpha should be used only by physicians experienced in infertility problems and their management, with appropriate monitoring facilities
- Mild to moderate uncomplicated ovarian enlargement accompanied by abdominal distension and/or abdominal pain has been reported with gonadotropins. To minimize the risk of overstimulation, monitor the ovarian response
- To reduce the chances of developing ovarian hyperstimulation syndrome (OHSS), if ovaries are abnormally enlarged, do not administer hCG
- Ovarian Hyperstimulation Syndrome (OHSS) is a serious medical condition that can occur with use of this product. It is manifested as severe pelvic pain, nausea, vomiting, weight gain, abdominal pain, abdominal distension, severe ovarian enlargement and dyspnea. Hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, thromboembolic reactions, and abnormal liver function tests have been reported
- OHSS mostly occurs after treatment has been discontinued, reaches its maximum at about seven to ten days following treatment, and resolves with the onset of menses. Withhold hCG administration if OHSS develops prior to hCG administration
- If serious OHSS occurs, discontinue treatment immediately, hospitalize the patient, and consult a physician experienced in the management of this syndrome and management of fluid and electrolyte imbalances
- Gonadotropin therapy, including lutropin can cause multi-fetal gestation and births. Before starting treatment, patient should be advised of the potential risk of multi-fetal gestation and births
- Gonadotropin therapy can cause serious pulmonary conditions such as arterial thromboembolism. Monitor the patient for signs and symptoms of thromboembolic events
- Lutropin alpha therapy should be started after proper diagnosis of infertility and proper selection of candidate
- Use sonographic visualization of the ovaries and endometrial lining in conjunction with measurement of serum estradiol levels to determine the degree of follicular maturation and the timing of hCG administration and also to minimize the risk of OHSS, multi-fetal gestation and ectopic pregnancy
Supplemental Patient Information
- Patients should be informed of the duration of treatment and monitoring of their condition that will be required
- Patients should be informed about the risks of ovarian hyperstimulation syndrome and multiple births
Pregnancy Category:X
Breastfeeding: Safety unknown. It is unknown whether lutropin alfa is excreted in human milk, as many drugs are excreted in human milk manufacturer advises caution while administering the nursing women.
